CEMP Stock UPDATES Cempra Inc (CEMP) 12.19 10/22/2014 07:14:

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 8:14 AM

Cempra Inc (CEMP) 12.19 $CEMP

Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on October 29, 2014
GlobeNewswire - 21 mins ago
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2014 financial results after the close of U.S. financial markets on October 29, 2014. Cempra management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
CEMP: 12.19 (-0.03)

Enanta (ENTA) Worth Watching: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:41AM CDT
Enanta Pharmaceuticals (ENTA) was a big mover last session, with shares rising nearly 7% on the day.
MNK: 89.30 (+2.15), LCI: 44.96 (+1.04), CEMP: 12.19 (-0.03), ENTA: 41.83 (-4.76)

ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as the company saw its shares surge nearly 14% on the day
LCI: 44.96 (+1.04), IMGN: 8.84 (-0.62), CEMP: 12.19 (-0.03), ENTA: 41.83 (-4.76)

Tetraphase (TTPH) in Focus: Stock Gains 19.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:46AM CDT
Tetraphase Pharmaceuticals (TTPH) was a big mover last session, with shares rising nearly 20% on the day.
MNK: 89.30 (+2.15), LCI: 44.96 (+1.04), TTPH: 23.89 (+0.34), CEMP: 12.19 (-0.03)

ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:32AM CDT
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
CCXI: 5.56 (+0.22), AMPE: 3.70 (-0.30), CEMP: 12.19 (-0.03), ENTA: 41.83 (-4.76)

Aquinox Pharmaceuticals (AQXP) Jumps: Stock Soars 22.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:27AM CDT
Aquinox Pharmaceuticals (AQXP) was a big mover last session, with shares surging over 22% on the day.
LCI: 44.96 (+1.04), ACT: 232.13 (+5.46), AQXP: 7.42 (+0.25), CEMP: 12.19 (-0.03)

Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:55AM CDT
Tetraphase has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
TTPH: 23.89 (+0.34), AMPE: 3.70 (-0.30), CEMP: 12.19 (-0.03), ENTA: 41.83 (-4.76)

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 14.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:25AM CDT
BioCryst Pharmaceuticals (BCRX) was a big mover last session, with shares rising nearly 15% on the day.
LCI: 44.96 (+1.04), BCRX: 11.37 (-0.23), SHPG: 185.80 (+1.21), CEMP: 12.19 (-0.03)

Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.12 (unch), AMPE: 3.70 (-0.30), CEMP: 12.19 (-0.03), CORT: 3.01 (+0.01)

Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:46AM CDT
Egalet (EGLT) was a big mover last session, with shares rising over 7% on the day.
LCI: 44.96 (+1.04), EGLT: 5.73 (+0.86), SHPG: 185.80 (+1.21), CEMP: 12.19 (-0.03)

Strength Seen in Sucampo (SCMP): Stock Rises 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:25AM CDT
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 9% on the day.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), SCMP: 8.00 (+0.06), CEMP: 12.19 (-0.03)

Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 22.80 (+0.71), AMPE: 3.70 (-0.30), CEMP: 12.19 (-0.03), CORT: 3.01 (+0.01)

PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:42AM CDT
PTC Therapeutics stock fell over 5% last trading session, continuing its recent downtrend
LCI: 44.96 (+1.04), PTCT: 37.90 (+0.34), CEMP: 12.19 (-0.03), CORT: 3.01 (+0.01)

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
HAWKB: 32.80 (+0.18), CBK: 6.39 (+0.01), CDTI: 1.55 (-0.13), CEMP: 12.19 (-0.03)

Strength Seen in Alcobra (ADHD): Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 8:25AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising over 6% on the day.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), ADHD: 5.12 (-0.20), CEMP: 12.19 (-0.03)

NanoViricides, Inc. (NNVC) in Focus: Stock Jumps 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:21AM CDT
NanoViricides, Inc. (NNVC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 44.96 (+1.04), CEMP: 12.19 (-0.03), NNVC: 3.66 (+0.10), HPTX: 22.75 (+0.08)

Esperion Therapeutics (ESPR) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:18AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by over 5% on the day.
LCI: 44.96 (+1.04), ESPR: 22.80 (+0.71), CEMP: 12.19 (-0.03), HPTX: 22.75 (+0.08)

Durata Therapeutics, Inc. (DRTX) Surges: Stock Rises 17.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:11AM CDT
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise over 17% on the day.
DRTX: 24.09 (+0.41), LCI: 44.96 (+1.04), CEMP: 12.19 (-0.03), HPTX: 22.75 (+0.08)

Alcobra (ADHD) Crumbles: Stock Falls by 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:47AM CDT
Alcobra stock fell over 7% last trading session, continuing its recent downtrend
LCI: 44.96 (+1.04), ADHD: 5.12 (-0.20), CEMP: 12.19 (-0.03), HPTX: 22.75 (+0.08)

Can the Uptrend Continue for Cempra (CEMP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:45AM CDT
Can the Uptrend Continue for Cempra (CEMP)?
CEMP: 12.19 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Class Action Greenlighted Against Concordia for Title IX Violations

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

WeFetch AI: A New Era in Barcode Precision

By Logan Wright Updated Nov 13, 2026 Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

vVARDIS Debuts on NYSE: Transforming Dental Care

A New Chapter for Dental Tech Mark your calendars, folks. vVARDIS is stepping onto the New York Stock Exchange (NYSE) stage, waving the banner of NYSE:VVVV. Now, if you've ever sat in that squeaky dental chair feeling the dread of a drill, vVARDIS might just be the new hero in town. Founded by the dynamic duo, Dr. Haley and Dr. Goly Abivardi, they're on a mission to...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...